Without the manufacturing expense, the quarterly expenditure will be $20M per quarter with over half on R&D which will allow them to claim at most 50% rebate on those expense. The pps will increase as more clinical trial updates are released and the market will price their MC with less risk and volatility as the IP development advances (I'm surprise the pps has dropped so much despite waiting for 8 months on the clinical update but that's the market for you).
Without the manufacturing expense, the quarterly expenditure...
-
- There are more pages in this discussion • 773 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.3¢ | 5.1¢ | $456.5K | 8.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 130988 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 1806964 | 23 |
View Market Depth
| Last trade - 13.44pm 23/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |